JPS6364427B2 - - Google Patents
Info
- Publication number
- JPS6364427B2 JPS6364427B2 JP15902380A JP15902380A JPS6364427B2 JP S6364427 B2 JPS6364427 B2 JP S6364427B2 JP 15902380 A JP15902380 A JP 15902380A JP 15902380 A JP15902380 A JP 15902380A JP S6364427 B2 JPS6364427 B2 JP S6364427B2
- Authority
- JP
- Japan
- Prior art keywords
- melting point
- methyl
- acid
- lower alkyl
- general formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
Landscapes
- Quinoline Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
【発明の詳細な説明】 本発明は一般式[Detailed description of the invention] The present invention is based on the general formula
【式】 または【formula】 or
【式】
〔式中、R1は水素、低級アルキルを、R2,R3
は同一または異なつて水素、低級アルキルを、
R4は水素、低級アルキル、ハロゲンを、R5は水
素、低級アルキルを、R6は水素、低級アルキル
を示す。〕
で表わされる新規なベンゾキノリン誘導体に関す
る。
一般式〔〕または〔′〕の記号の定義を具
体的に示すと、低級アルキルとはメチル、エチ
ル、プロピル、ブチルなどを、ハロゲンとは塩
素、フツ素、臭素などを示す。
一般式〔〕または〔′〕で表わされる化合
物は血小板凝集抑制作用、鎮痛作用などを有し医
薬として、有用である。また向精神作用、鎮痛作
用、消炎作用、抗血栓作用を有する化合物の中間
体としても有用である。
一般式〔〕または〔′〕の化合物は、たと
えば、一般式
〔式中、R1,R2,R3,R4,R5およびR6は前記
と同義である。〕
で表わされるカルボン酸またはその反応性誘導体
(たとえば酸ハライド)を、ルイス酸(たとえば、
硫酸、ポリリン酸、塩化アルミニウムなど)の存
在下で、縮合閉環させることにより製造される。
縮合閉環反応は、一般式〔〕において、カル
ボン酸である場合には、縮合閉環反応の一般的方
法が適用され、たとえば、濃硫酸中、室温〜150
℃、1〜10時間で好適に進行する。
一般式〔〕の原料化合物の一部は特開昭52―
73875号に開示されているが、一般式
で表わこれるγ―ケト酸、または特開昭54―
135785号に開示されている一般式
で表わされるピリダジノン化合物にウオルフ・キ
ツシユナー還元反応を行なうことにより、好収率
で調製される。
参考例 1
4―(1,2,3,4―テトラヒドロ―2―オ
キソキノリン―6―イル)―4―オキソブタン酸
37g、苛性カリ59g、80%ヒドラジン・ヒドラー
ト60mlをトリエチレングリコール200ml中に加え
る。かきまぜながら、徐々に温度を上昇させ、
190〜200℃に1時間保つ。放冷後、あらかじめ濃
塩酸を加えている氷水中へ、反応物を注ぎ込む。
生じた結晶を取し、水洗後、乾燥すると、4―
(1,2,3,4―テトラヒドロ―2―オキソキ
ノリン―6―イル)ブタン酸が30.7g得られる。
融点185〜188℃。
参考例 2
6―(1―メチル―2―オキソ―1,2,3,
4―テトラヒドロキノリン―6―イル)―4,5
―ジヒドロ―5―メチル―3(2H)―ピリダジノ
ン136g、苛性カリ168g、80%ヒドラジン・ヒド
ラート200mlをトリエチレングリコール600ml中に
加え、徐々に加熱し、190〜200℃に2時間保つ。
放冷後、反応物を、あらかじめ濃塩酸を加えてい
る氷水中に注ぎ込む。生じた結晶を取し、水洗
後、乾燥すると、4―(1―メチル―2―オキソ
―1,2,3,4―テトラヒドロキノリン―6―
イル)―3―メチルブタン酸が115g得られる。
融点114〜116℃
同様にして以下の原料化合物〔〕が得られ
る。
◎ 4―(1―メチル―2―オキソ―1,2,
3,4―テトラヒドロキノリン―6―イル)ブ
タン酸 融点144〜145℃
◎ 4―(4―メチル―2―オキソ―1,2,
3,4―テトラヒドロキノリン―6―イル)ブ
タン酸 融点164〜165℃
◎ 4―(1―メチル―2―オキソ―1,2,
3,4―テトラヒドロキノリン―6―イル)―
2―メチルブタン酸 融点108〜111℃
◎ 4―(7―メチル―2―オキソ―1,2,
3,4―テトラヒドロキノリン―6―イル)ブ
タン酸 融点242〜244℃
◎ 4―(8―クロロ―2―オキソ―1,2,
3,4―テトラヒドロキノリン―6―イル)―
3―メチルブタン酸 融点137〜139℃
つぎに本発明を実施例を挙げて具体的に説明す
る。
実施例 1
4―(1―メチル―2―オキソ―1,2,3,
4―テトラヒドロキノリン―6―イル)ブタン酸
23.5gを濃硫酸120ml中に加え、100〜110℃に1
時間保つ。ついで、反応物を氷中へ注ぎ込み、生
じた結晶を取し、水洗する。エタノールから再
結晶すると、無色針状晶の1―メチル―2,9―
ジオキソ―1,2,3,4,6,7,8,9―オ
クタヒドロベンゾ〔g〕キノリンが16.7g得られ
る。融点173〜174℃
実施例 2
4―(7―メチル―2―オキソ―1,2,3,
4―テトラヒドロキノリン―6―イル)ブタン酸
30gを濃硫酸150ml中に加え、100〜110℃に2時
間保つ。ついで、反応物を氷中に注ぎ込み、生じ
た結晶を取し、水洗する。エチルアルコールか
ら再結晶すると、無色針状晶の6―メチル―3,
10―ジオキソ―1,2,3,4,7,8,9,10
―オクタヒドロベンゾ〔f〕キノリンが22.3g得
られる。融点232〜233℃
同様にして、さらに次の化合物が得られる。
実施例 3
2,9―ジオキソ―1,2,3,4,6,7,
8,9―オクタヒドロベンゾ〔g〕キノリン 融
点284〜285℃
実施例 4
1―ブチル―2,9―ジオキソ―1,2,3,
4,6,7,8,9―オクタヒドロベンゾ〔g〕
キノリン 融点96〜98℃
実施例 5
4―メチル―2,9―ジオキソ―1,2,3,
4,6,7,8,9―オクタヒドロベンゾ〔g〕
キノリン 融点230〜231℃
実施例 6
1,7―ジメチル―2,9―ジオキソ―1,
2,3,4,6,7,8,9―オクタヒドロベン
ゾ〔g〕キノリン 融点157〜158℃
実施例 7
1,8―ジメチル―2,9―ジオキソ―1,
2,3,4,6,7,8,9―オクタヒドロベン
ゾ〔g〕キノリン 融点182〜185℃
実施例 8
10―クロロ―7―メチル―2,9―ジオキソ―
1,2,3,4,6,7,8,9―オクタヒドロ
ベンゾ〔g〕キノリン 融点199〜200℃
実施例 9
5―クロロ―8―メチル―3,10―ジオキソ―
1,2,3,4,7,8,9,10―オクタヒドロ
ベンゾ〔f〕キノリン 融点145〜146℃。[Formula] [In the formula, R 1 is hydrogen or lower alkyl, R 2 , R 3
are the same or different hydrogen, lower alkyl,
R 4 represents hydrogen, lower alkyl or halogen; R 5 represents hydrogen or lower alkyl; R 6 represents hydrogen or lower alkyl. ] This invention relates to a novel benzoquinoline derivative represented by: To specifically define the symbols in the general formula [] or ['], lower alkyl refers to methyl, ethyl, propyl, butyl, etc., and halogen refers to chlorine, fluorine, bromine, etc. The compound represented by the general formula [] or ['] has platelet aggregation inhibiting action, analgesic action, etc., and is useful as a medicine. It is also useful as an intermediate for compounds having psychotropic, analgesic, antiinflammatory, and antithrombotic effects. The compound of the general formula [] or [′] is, for example, a compound of the general formula [In the formula, R 1 , R 2 , R 3 , R 4 , R 5 and R 6 have the same meanings as above. ] The carboxylic acid represented by or its reactive derivative (e.g. acid halide) is combined with a Lewis acid (e.g.
It is produced by condensation and ring closure in the presence of sulfuric acid, polyphosphoric acid, aluminum chloride, etc.). When the condensation ring-closing reaction is a carboxylic acid in the general formula [], a general method for the condensation ring-closing reaction is applied, for example, in concentrated sulfuric acid at room temperature to 150 °C.
C. for 1 to 10 hours. Some of the raw material compounds of the general formula [] are JP-A-52-
Although disclosed in No. 73875, the general formula The γ-keto acid represented by
General formula disclosed in No. 135785 It is prepared in good yield by subjecting the pyridazinone compound represented by the following to Wolff-Kitsschner reduction reaction. Reference example 1 4-(1,2,3,4-tetrahydro-2-oxoquinolin-6-yl)-4-oxobutanoic acid
Add 37 g of caustic potash, 59 g of caustic potash, and 60 ml of 80% hydrazine hydrate in 200 ml of triethylene glycol. While stirring, gradually raise the temperature,
Keep at 190-200℃ for 1 hour. After cooling, the reaction mixture is poured into ice water to which concentrated hydrochloric acid has been added.
When the crystals formed are collected, washed with water, and dried, 4-
30.7 g of (1,2,3,4-tetrahydro-2-oxoquinolin-6-yl)butanoic acid are obtained.
Melting point 185-188℃. Reference example 2 6-(1-methyl-2-oxo-1,2,3,
4-tetrahydroquinolin-6-yl)-4,5
Add 136 g of -dihydro-5-methyl-3(2H)-pyridazinone, 168 g of caustic potash, and 200 ml of 80% hydrazine hydrate to 600 ml of triethylene glycol, gradually heat and keep at 190-200°C for 2 hours.
After cooling, the reaction mixture was poured into ice water to which concentrated hydrochloric acid had been added in advance. The resulting crystals are collected, washed with water, and dried to give 4-(1-methyl-2-oxo-1,2,3,4-tetrahydroquinoline-6-
115 g of yl)-3-methylbutanoic acid are obtained.
Melting point: 114-116°C The following raw material compound [] is obtained in the same manner. ◎ 4-(1-methyl-2-oxo-1,2,
3,4-tetrahydroquinolin-6-yl)butanoic acid Melting point 144-145℃ ◎ 4-(4-methyl-2-oxo-1,2,
3,4-tetrahydroquinolin-6-yl)butanoic acid Melting point 164-165℃ ◎ 4-(1-methyl-2-oxo-1,2,
3,4-tetrahydroquinolin-6-yl)-
2-Methylbutanoic acid Melting point 108-111℃ ◎ 4-(7-methyl-2-oxo-1,2,
3,4-tetrahydroquinolin-6-yl)butanoic acid Melting point 242-244℃ ◎ 4-(8-chloro-2-oxo-1,2,
3,4-tetrahydroquinolin-6-yl)-
3-Methylbutanoic acid Melting point: 137-139°C Next, the present invention will be specifically explained with reference to Examples. Example 1 4-(1-methyl-2-oxo-1,2,3,
4-tetrahydroquinolin-6-yl)butanoic acid
Add 23.5g to 120ml of concentrated sulfuric acid and heat to 100-110℃.
Keep time. Then, the reaction mixture is poured into ice, and the crystals formed are collected and washed with water. Recrystallization from ethanol gives colorless needle-shaped crystals of 1-methyl-2,9-
16.7 g of dioxo-1,2,3,4,6,7,8,9-octahydrobenzo[g]quinoline are obtained. Melting point 173-174℃ Example 2 4-(7-methyl-2-oxo-1,2,3,
4-tetrahydroquinolin-6-yl)butanoic acid
Add 30g to 150ml of concentrated sulfuric acid and keep at 100-110°C for 2 hours. Then, the reaction mixture is poured into ice, and the crystals formed are collected and washed with water. When recrystallized from ethyl alcohol, colorless needle-shaped crystals of 6-methyl-3,
10-dioxo-1,2,3,4,7,8,9,10
-22.3g of octahydrobenzo[f]quinoline is obtained. Melting point: 232-233°C Similarly, the following compound is obtained. Example 3 2,9-dioxo-1,2,3,4,6,7,
8,9-octahydrobenzo[g]quinoline Melting point 284-285°C Example 4 1-Butyl-2,9-dioxo-1,2,3,
4,6,7,8,9-octahydrobenzo [g]
Quinoline Melting point 96-98℃ Example 5 4-Methyl-2,9-dioxo-1,2,3,
4,6,7,8,9-octahydrobenzo [g]
Quinoline Melting point 230-231℃ Example 6 1,7-dimethyl-2,9-dioxo-1,
2,3,4,6,7,8,9-octahydrobenzo[g]quinoline Melting point 157-158°C Example 7 1,8-dimethyl-2,9-dioxo-1,
2,3,4,6,7,8,9-octahydrobenzo[g]quinoline Melting point 182-185°C Example 8 10-chloro-7-methyl-2,9-dioxo-
1,2,3,4,6,7,8,9-octahydrobenzo[g]quinoline Melting point 199-200°C Example 9 5-chloro-8-methyl-3,10-dioxo-
1,2,3,4,7,8,9,10-octahydrobenzo[f]quinoline Melting point 145-146°C.
Claims (1)
は同一または異なつて、水素、低級アルキルを、
R4は水素、低級アルキル、ハロゲンを、R5は水
素、低級アルキルを、R6は水素、低級アルキル
を示す。〕 で表わされるベンゾキノリン誘導体。[Claims] 1 General formula [Formula] or [Formula] [In the formula, R 1 is hydrogen or lower alkyl, R 2 , R 3
are the same or different, hydrogen, lower alkyl,
R 4 represents hydrogen, lower alkyl, or halogen, R 5 represents hydrogen or lower alkyl, and R 6 represents hydrogen or lower alkyl. ] A benzoquinoline derivative represented by.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP15902380A JPS5782371A (en) | 1980-11-11 | 1980-11-11 | Benzoquinoline derivative and its preparation |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP15902380A JPS5782371A (en) | 1980-11-11 | 1980-11-11 | Benzoquinoline derivative and its preparation |
Publications (2)
Publication Number | Publication Date |
---|---|
JPS5782371A JPS5782371A (en) | 1982-05-22 |
JPS6364427B2 true JPS6364427B2 (en) | 1988-12-12 |
Family
ID=15684560
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP15902380A Granted JPS5782371A (en) | 1980-11-11 | 1980-11-11 | Benzoquinoline derivative and its preparation |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPS5782371A (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1984001948A1 (en) * | 1982-11-10 | 1984-05-24 | Yoshitomi Pharmaceutical | BENZO ADf BD QUINOLINE DERIVATIVES |
JPS61186365A (en) * | 1985-02-14 | 1986-08-20 | Yoshitomi Pharmaceut Ind Ltd | Benzo(f)quinoline derivative |
-
1980
- 1980-11-11 JP JP15902380A patent/JPS5782371A/en active Granted
Also Published As
Publication number | Publication date |
---|---|
JPS5782371A (en) | 1982-05-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR840001612B1 (en) | Method for preparing quinolone compound | |
SU862824A3 (en) | Method of preparing phenylhydrazinopyridazines | |
JPS6364427B2 (en) | ||
HU198709B (en) | Process for producing quinoline-carboxylic acid derivatives | |
US2344459A (en) | Method of preparing i | |
JP4026233B2 (en) | Method for producing 4,5-dichloro-6- (α-fluoroalkyl) pyrimidine | |
DE1695702B2 (en) | PROCESS FOR THE PRODUCTION OF 1ACYL-2-CARBOXY-3-INDOLYL ACID ACIDS | |
US1073380A (en) | N-halogenalkyl-c c-dialkylbarbituric acids and preparation of the same. | |
JP2000229944A (en) | Production of 6-hydroxy-2-oxo-1,2,3,4-terrahydroquinoline | |
JPH0319228B2 (en) | ||
JP6312718B2 (en) | Method for preparing deferasirox | |
JPS6160832B2 (en) | ||
JPS63502429A (en) | Amifloxacin intermediate | |
JPH11292873A (en) | Method for producing quinolone carboxylic acid derivative and intermediate thereof | |
WO2008020453A2 (en) | A process for the preparation of a novel crystalline polymorph of aripiprazole | |
JPS645024B2 (en) | ||
JPH0774218B2 (en) | Benzopyranotriazole derivative | |
JPH0474353B2 (en) | ||
US2807623A (en) | Certain aryl mercapto methyl imidazoles | |
PL165452B1 (en) | Method for the production of a new quinoline salt PL PL PL | |
JPS585902B2 (en) | β↓-nitrostyrene derivative | |
Duff | CCIII.—p-Toluoylacetic acid, o-nitro-p-toluoylacetic acid, and 6: 6′-dimethylindigotin | |
JPS6197263A (en) | Manufacture of indole derivative | |
Phillips | a Synthesis of Thymol from Para Cymene. Ii | |
JP4055246B2 (en) | 5-chloro-6- (α-fluoroalkyl) -4-pyrimidone and process for producing the same |